MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve myelofibrosis
Last Updated: Tuesday, April 11, 2023
According to the results from the open-label, nonrandomized, multicohort, phase II MANIFEST study, combination therapy with bromodomain and extraterminal domain inhibitor pelabresib plus ruxolitinib was well tolerated and efficacious in JAKi-naïve patients with myelofibrosis. At 24 weeks, 68% of patients achieved spleen volume reduction of ≥ 35%, and 56% achieved a total symptom score reduction of ≥ 50% (TSS50).
Advertisement
News & Literature Highlights
